Skip to main content
Sinocare Inc. logo

Sinocare Inc. — Investor Relations & Filings

Ticker · 300298 ISIN · CNE100001CJ0 LEI · 3003008DEKI00A51LU77 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,252 across all filing types
Latest filing 2014-02-26 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 300298

About Sinocare Inc.

https://www.sinocare.com

Sinocare Inc. specializes in the research, development, and manufacturing of biosensor technology and rapid testing products for chronic disease management. The company is primarily recognized for its blood glucose monitoring systems, including meters and test strips, which serve a global patient base. Its product portfolio extends to point-of-care testing (POCT) solutions for HbA1c, uric acid, blood lipids, and other metabolic indicators. Through the integration of advanced sensing technologies and digital health platforms, Sinocare provides comprehensive diagnostic tools for diabetes and related metabolic disorders. The company focuses on delivering affordable and accurate monitoring solutions to improve the quality of life for individuals with chronic conditions worldwide.

Recent filings

Filing Released Lang Actions
2013年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2013 年度业绩快报' which translates to '2013 Annual Performance Express Report' or '2013 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2013, including revenue, profit, net income, earnings per share, and other financial metrics. The document explicitly states that the data is preliminary and unaudited, and that the final audited data will be disclosed in the 2013 Annual Report. The document is relatively short (1864 characters) and serves as an initial earnings announcement rather than a full annual report. It provides key financial highlights and a brief explanation of business performance and changes, which aligns with the definition of an Earnings Release (ER) as an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K), nor an Audit Report (AR), nor a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive financial data and analysis, not just a notice or certification. Therefore, the correct classification is Earnings Release (ER). FY 2013
2014-02-26 Chinese
关于使用部分超募资金认购华广生技股份有限公司私募股份的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the use of excess raised funds (超募资金) by the company 三诺生物传感股份有限公司 to subscribe for private placement shares of 华广生技股份有限公司. It details the background of the fundraising, the approval process by the board and independent directors, the financial data of the target company, risk disclosures, and regulatory compliance references. The document is structured as a formal announcement to shareholders and the public about a specific capital use decision, including approvals and opinions from relevant parties. It does not contain comprehensive financial statements or detailed financial performance data of the reporting company itself, nor is it a transcript, audit report, or earnings release. It is not a full annual or interim report but rather a regulatory announcement about a capital use event involving private placement subscription. Given the content and nature, this fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length (6202 characters) and detailed content support this classification with high confidence.
2014-02-26 Chinese
关于与华广生技股份有限公司签订《战略合作框架协议书》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a strategic cooperation framework agreement between the company and another entity. It details the nature of the cooperation, the parties involved, the scope, and the intended outcomes. There is no financial data, no detailed financial report, no earnings information, no management discussion of financial results, and no regulatory certification. The document is relatively short (2268 characters) and serves as a formal announcement of a corporate agreement rather than a report or detailed filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or M&A filings. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories.
2014-02-26 Chinese
第二届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 三诺生物传感股份有限公司 regarding decisions made in their sixth meeting. It includes approval of strategic cooperation agreements, private placement subscription agreements, and use of funds for private placement shares. The document references that these matters will be submitted to the shareholders' meeting for approval. The document length is 1805 characters, which is relatively short and primarily contains meeting resolutions and voting results. It does not contain financial statements, detailed financial data, or comprehensive report content. It is not an annual or interim report, earnings release, or audit report. It is not a proxy solicitation or voting results declaration but a meeting resolution announcement by the Supervisory Board. Given the nature of the content and the short length, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2014-02-26 Chinese
中信证券股份有限公司关于公司超募资金使用计划的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of over-raised funds by SanNuo Bio-sensing Co., Ltd. It discusses the company's fundraising details, the plan to invest excess funds into another company (Hua Guang Biotech), legal and financial analyses, and compliance with regulatory requirements. The document includes references to regulatory rules, board meeting approvals, and investment risk assessments. It is not a full financial report like an Annual or Interim Report, nor is it a brief announcement or a certification. It is a formal audit or verification opinion related to the use of raised funds, which fits the category of an Audit Report / Information (AR). The length (5298 characters) and content support this classification as it contains substantive analysis and verification rather than just an announcement or summary. Q1 2014
2014-02-26 Chinese
关于重大事项继续停牌的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the continuation of a trading suspension (停牌) due to a major pending investment matter with uncertainty. It references a previous announcement about the suspension and states that the suspension will continue until further notice. There are no financial statements, detailed financial data, or report contents. The document is a regulatory announcement about trading status related to a significant corporate event, not a full report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2014-02-21 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.